Summary
Updated Aug 31, 2026
Christopher Haqq is Executive Vice President, Head of R&D and Chief Medical Officer of Elicio Therapeutics, Inc. (ELTX). 3 SEC Form 4 filings on record going back to 2024, most recently on 17 July 2026.
Recent Transactions
1Every recent SEC Form 4 transaction Christopher Haqq has reported, most recent first.
Trading Pattern
InsiderAlpha's records for Christopher Haqq go back to 2024: 3 primary Form 4 filings, an average of 1.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Sector
No other insider has filed at Christopher Haqq's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- August J. Troendle - $249.99M of MEDP open-market activity in the last 12 months
- A/S Genmab - $234.86M of MRUS open-market activity in the last 12 months
- Weiss Asset Management LP - $233.35M of AVDL open-market activity in the last 12 months
- James Edgemond - $201.52M of UTHR open-market activity in the last 12 months
- Scilex Holding Co - $200.00M of SMNR open-market activity in the last 12 months
- Michael Benkowitz - $199.02M of UTHR open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Christopher Haqq?
Christopher Haqq is a corporate insider, tracked as Executive Vice President, Head of R&D and Chief Medical Officer of Elicio Therapeutics, Inc. (ELTX). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Christopher Haqq submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Where can I see all of Christopher Haqq's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Christopher Haqq and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial